The strong performance the company has delivered in Q2 reflected the strength of the business fundamentals, sustained execution and the resilience of its diversified product portfolio.
Aurobindo Pharma Q2 net up 32.5% to ₹1,124 cr on higher revenue
Published ·
Keep reading
Related stories
